Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Pinterest

- PMLiVE

Novartis’ heart failure drug could get FDA nod in summer

Some predicting sales of $5bn within four years for LCZ696

- PMLiVE

Personalised cancer medicines showcased in BBC investigation

Panorama looked at cutting-edge science and the new generation of oncology drugs

Novartis building

Novartis’ Japanese subsidiary threatened with suspension

Company failed to report more than 3,200 adverse events among patients taking its drugs

Novartis building

Novartis sees first benefits from efficiency drive

Made $1.6bn in savings in 2014

- PMLiVE

Novartis begins sale talks for Horsham, UK site

Enters negotiations with the University of Brighton

- PMLiVE

Novartis launches another localised NHS eye service in UK

Will provide specialised care to people of Coventry

- PMLiVE

Novartis’ Cosentyx cleared for psoriasis in Europe

First of the IL-17 inhibitor classof drug to receive European approval

- PMLiVE

Novartis forms digital health investment company with Qualcomm

Expands work with Tricorder prize firm to develop 'beyond-the-pill' initiatives

Novartis building

Novartis files COPD combo in US

QVA149 combines long-acting beta agonist with long-acting muscarinic antagonist

- PMLiVE

Novartis completes sale of animal health unit to Lilly

$5.4bn deal is finalised

- PMLiVE

Novartis signs stem cell research pact with Intellia

Will work with the biotech start-up on creating new treatments

Novartis day

FDA close to first biosimilar approval

US regulator’s advisory board recommends Novartis’ version of Amgen’s Neupogen

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links